Complex Rendelo Med Zrt.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Research at Complex Rendelo Med Zrt. focuses on conditions such as heart failure, atherosclerotic disease, and disorders of lipid metabolism, aiming to improve survival and reduce cardiovascular events.
- Evaluation of novel therapies for heart failure with reduced ejection fraction
- Combination studies of kidney‑protective agents and heart failure treatments
- Lipid‑lowering strategies targeting hyperlipidemia and familial hypercholesterolaemia
- Prevention of cardiovascular outcomes in patients with obesity and atherosclerotic disease
The site conducts 27 trials with 11 investigators, providing patients in Szekesfehervar access to cutting‑edge cardiovascular research.
Immune System Diseases
The centre’s immune‑focused program investigates autoimmune conditions including primary Sjogren’s disease and systemic inflammatory disorders, seeking safer and more effective immunomodulation.
- JAK‑inhibitor studies for active psoriatic arthritis
- Safety assessment of new cytokine blockers in autoimmune disease
- Combination therapy trials for refractory immune‑mediated arthritis
- Long‑term tolerability of targeted agents in systemic autoimmune conditions
As a non‑commercial hospital, Complex Rendelo Med Zrt. offers participants the chance to contribute to therapies that could reshape immune disease management.
Musculoskeletal Diseases
Studies in this therapeutic area address debilitating joint disorders such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with a focus on disease control and functional improvement.
- Head‑to‑head comparison of biosimilar and reference biologics in rheumatoid arthritis
- Evaluation of oral small‑molecule agents for active psoriatic arthritis
- Long‑term safety of disease‑modifying antirheumatic drugs (DMARDs)
- Patient‑reported outcome measures in axial spondyloarthritis treatment
With a portfolio of 27 clinical trials, the site enables patients to access innovative musculoskeletal therapies while supporting scientific advancement.
Skin and Connective Tissue Diseases
Research targeting skin‑related and connective‑tissue conditions explores agents that modulate inflammatory pathways, aiming to alleviate skin lesions and systemic manifestations.
- IL‑17 inhibition trials for psoriasis‑associated arthritis
- Assessment of skin symptom control with new biologics
- Targeted therapies for connective tissue involvement in systemic disease
- Quality‑of‑life outcomes in patients receiving novel skin‑focused treatments
Located in Szekesfehervar, Complex Rendelo Med Zrt. provides a collaborative environment where 11 investigators advance care for patients with skin and connective tissue disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1AstraZeneca AB4active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complex Rendelo Med Zrt.
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2024-06-05 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.